Total
0
Shares
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald
CEO & Managing Director, Brent Barnes
Source: LBT Innovations
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical technology player LBT Innovations (LBT) has pocketed $830,000 under a government research and development tax incentive
  • The company received the cash boost under the Australian government's research and development tax rebate, which aims to incentivise spending in that area
  • LBT is currently developing its new Automated Plate Assessment System Antimicrobial Resistance analysis module, which is regarded as the only U.S. Food and Drug Administration cleared artificial intelligence technology of its kind
  • LBT Innovations shares are off 3.54 per cent on the market, trading at 9.6 cents

Medical technology player LBT Innovations (LBT) has pocketed $830,000 under a government research and development tax incentive.

The cash boost received from the Australian Tax Office (ATO) for the financial year ended 30 June 2020 relates to expenditure on eligible Australian research and development (R&D) activities LBT undertook during the 2019/2020 financial year.

It forms part of LBT's broader recognised current tax asset of $1.18 million, of which the $830,000 received is attributable to the 2020 R&D claim lodged earlier this year.

According to the ATO, the incentive from the Australian government provides targeted tax offsets to encourage more companies to engage in research and development activities.

LBT is currently developing its new Automated Plate Assessment System Antimicrobial Resistance analysis module through its 50-per-cent-owned joint venture company Clever Culture Systems AG with Hettich Holding Beteiligungs- und Verwaltungs-GmbH.

The instrument is regarded as only U.S. Food and Drug Administration cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

LBT Innovations shares are off 3.54 per cent on the market, trading at 9.6 cents at 3:13 pm AEDT.

More From The Market Herald
Anatara Lifesciences (ASX:ANR) - CEO, Steven Lydeamore - The Market Herald

" Anatara Lifesciences (ASX:ANR) secures patent for animal health product

Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation for its animal health product, Detach.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) advances new clinical trials

Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327.
Mayne Pharma (ASX:MYX) - CEO, Scott Richards - The Market Herald

" Mayne Pharma’s (ASX:MYX) oral contraceptive receives FDA approval

Mayne Pharma (MYX) and Mithra Pharmaceuticals have received approval for its combined oral contraceptive Nextstellis from the U.S. Food and Drug Administration (FDA).
Universal Biosensors (ASX:UBI) enters distribution deal with Wine & Beer Supply

" Universal Biosensors (ASX:UBI) enters distribution deal with Wine & Beer Supply

Universal Biosensors (UBI) has entered a deal with Wine & Beer Supply for the distribution of its wine testing device in the U.S.